RenovoRx Bets on Targeted Delivery as Pancreatic Cancer Trial Advances

NEW YORK, NY – November 19, 2025

A Novel Approach to a Deadly Disease

RenovoRx, Inc. (Nasdaq: RNXT) is set to present at the Alliance Global Partners (AGP) Emerging AgBiotech/Bio-Solutions Virtual Showcase today, highlighting its progress in targeted oncology and the ongoing Phase III trial for locally advanced pancreatic adenocarcinoma (LAPC). The small-cap biotech is attempting to carve out a niche with its RenovoCath device and Trans-Arterial Micro-Perfusion (TAMP) therapy platform – a method aiming to deliver chemotherapy directly to tumor sites, minimizing systemic side effects. While pancreatic cancer remains a notoriously difficult disease to treat, RenovoRx believes its innovative approach could offer a significant benefit to patients.

“The biggest challenge in treating pancreatic cancer is getting enough drug to the tumor while avoiding debilitating toxicity,” said one industry analyst covering the space. “Targeted delivery systems like RenovoRx’s could be a game-changer if they prove effective.”

TAMP: How it Works and the Competitive Landscape

The RenovoCath device is designed to temporarily occlude blood vessels, creating a localized pressure that forces chemotherapeutic agents directly into the tumor. This localized approach aims to maximize drug concentration at the site of the cancer while reducing exposure to healthy tissues. The company received initial FDA clearance for the device in 2014 and has since expanded the clearance to include the delivery of chemotherapeutic drugs.

However, the competitive landscape is increasingly crowded. Established pharmaceutical giants are also investing in targeted drug delivery technologies, and several emerging biotechs are developing innovative platforms. Companies are focusing on implantable devices, nanoparticles, and other methods to deliver drugs directly to tumors.

“There’s a lot of exciting innovation happening in this space,” said a source familiar with the sector. “But translating that innovation into a commercially viable product is the real challenge.”

Phase III Trial Progress and Financial Considerations

The ongoing Phase III TIGeR-PaC trial is crucial to RenovoRx’s future. The trial is evaluating the efficacy of intra-arterial gemcitabine (IAG) delivered via RenovoCath, compared to standard intravenous chemotherapy and radiation therapy. As of late March 2025, the trial had randomized 90 patients, and the company anticipates completing enrollment in early 2026.

Recent data suggests the company has experienced slower than anticipated revenue growth. Year-to-date revenue through September 30, 2025, reached approximately $900,000, falling short of analyst expectations. While the company has $10.0 million in cash and cash equivalents, management has indicated that current funds will not sustain operations for the next 12 months without additional funding. This raises questions about the company's ability to finance the completion of the trial and the potential commercialization of RenovoCath.

“Financing will be key for RenovoRx,” commented one analyst. “They’ve made progress with the trial, but they need to secure additional funding to continue their development efforts.”

Investor Showcase and Analyst Perspective

Today's presentation at the AGP showcase is an opportunity for RenovoRx to update investors on the progress of the TIGeR-PaC trial and its commercialization strategy. Alliance Global Partners has been following the company closely, recently maintaining a “Buy” rating despite lowering its price target following the latest earnings report. The analyst cited lower revenue forecasts and potential dilution as factors influencing the revised target.

AGP's coverage is a vote of confidence, but investors will be looking for clarity on the company's financial outlook and its plans to address the funding gap. The company's ability to execute its strategy and secure the necessary funding will be critical to its long-term success.

One source suggested that the upcoming interim analysis of the TIGeR-PaC trial, expected in the second half of 2025, will be a crucial catalyst for the stock. Positive data could attract additional investment and validate the company’s approach. However, any setbacks could raise concerns about the viability of the trial and the future of RenovoRx.

The company’s presentation today represents a pivotal moment, offering a glimpse into the potential of targeted therapy in pancreatic cancer and the challenges faced by small-cap biotechs striving to disrupt the established pharmaceutical landscape.